SG10201910521YA - Pharmaceutical Compositions Comprising (3-(1-(1H-Imidazol-4-yl)Ethyl)-2-Methylphenyl) Methanol - Google Patents
Pharmaceutical Compositions Comprising (3-(1-(1H-Imidazol-4-yl)Ethyl)-2-Methylphenyl) MethanolInfo
- Publication number
- SG10201910521YA SG10201910521YA SG10201910521YA SG10201910521YA SG10201910521YA SG 10201910521Y A SG10201910521Y A SG 10201910521YA SG 10201910521Y A SG10201910521Y A SG 10201910521YA SG 10201910521Y A SG10201910521Y A SG 10201910521YA SG 10201910521Y A SG10201910521Y A SG 10201910521YA
- Authority
- SG
- Singapore
- Prior art keywords
- imidazol
- methylphenyl
- methanol
- ethyl
- pharmaceutical compositions
- Prior art date
Links
- HTQCEFAVROSRIW-UHFFFAOYSA-N [3-[1-(1h-imidazol-5-yl)ethyl]-2-methylphenyl]methanol Chemical compound C=1C=CC(CO)=C(C)C=1C(C)C1=CNC=N1 HTQCEFAVROSRIW-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41418010P | 2010-11-16 | 2010-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201910521YA true SG10201910521YA (en) | 2020-01-30 |
Family
ID=44999965
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201509423XA SG10201509423XA (en) | 2010-11-16 | 2011-11-10 | Pharmaceutical Compositions Comprising (3-(1-(1H-Imidazol-4-yl)Ethyl)-2-Methylphenyl) Methanol |
| SG2013038153A SG190322A1 (en) | 2010-11-16 | 2011-11-10 | Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2- methylphenyl)methanol |
| SG10201910521YA SG10201910521YA (en) | 2010-11-16 | 2011-11-10 | Pharmaceutical Compositions Comprising (3-(1-(1H-Imidazol-4-yl)Ethyl)-2-Methylphenyl) Methanol |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201509423XA SG10201509423XA (en) | 2010-11-16 | 2011-11-10 | Pharmaceutical Compositions Comprising (3-(1-(1H-Imidazol-4-yl)Ethyl)-2-Methylphenyl) Methanol |
| SG2013038153A SG190322A1 (en) | 2010-11-16 | 2011-11-10 | Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2- methylphenyl)methanol |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US20120149747A1 (en) |
| EP (3) | EP3795154A1 (en) |
| JP (1) | JP2013542991A (en) |
| KR (8) | KR102134117B1 (en) |
| CN (1) | CN103298467A (en) |
| AR (1) | AR083893A1 (en) |
| AU (1) | AU2011329209B8 (en) |
| BR (1) | BR112013012112A2 (en) |
| CA (2) | CA2818144C (en) |
| DK (1) | DK3093017T3 (en) |
| ES (1) | ES2865118T3 (en) |
| IL (1) | IL226384A (en) |
| MX (1) | MX340859B (en) |
| RU (1) | RU2013124526A (en) |
| SG (3) | SG10201509423XA (en) |
| TW (1) | TW201304774A (en) |
| WO (1) | WO2012067941A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2395999B1 (en) | 2009-02-13 | 2017-09-13 | Allergan, Inc. | Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol |
| US9095576B2 (en) | 2011-11-21 | 2015-08-04 | Allergan, Inc. | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69823868T2 (en) * | 1997-12-04 | 2005-04-21 | Allergan Inc | SUBSTITUTED IMIDAZOLE DERIVATIVES WITH AGONISTIC EFFECT ON THE ALPHA 2B OR 2B / 2C ADRENERGIC RECEPTORS |
| US20020198210A1 (en) * | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Alpha-2-adrenergic agonist/fatty acid compositions |
| US7642258B2 (en) * | 2002-04-19 | 2010-01-05 | Allergan, Inc. | Combination of brimonidine and timolol for topical ophthalmic use |
| US7091232B2 (en) * | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US20050059744A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| CN1878569A (en) * | 2003-09-12 | 2006-12-13 | 阿勒根公司 | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| JP4955543B2 (en) * | 2004-05-25 | 2012-06-20 | サンズローザ ファーマシューティカル ディヴェロップメント インコーポレイテッド | Compounds, formulations and methods for treating or preventing inflammatory skin diseases |
| GB0611241D0 (en) * | 2006-06-07 | 2006-07-19 | Daniolabs Ltd | The treatment of increased sebum production |
| GB0715790D0 (en) | 2007-08-13 | 2007-09-26 | Summit Corp Plc | Drug combination for the treatment of sialorrhoea |
| PT2320911E (en) * | 2008-08-01 | 2014-11-11 | Eye Therapies Llc | Vasoconstriction compositions and methods of use |
| EP2395999B1 (en) | 2009-02-13 | 2017-09-13 | Allergan, Inc. | Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol |
-
2011
- 2011-11-10 JP JP2013539910A patent/JP2013542991A/en active Pending
- 2011-11-10 KR KR1020207007148A patent/KR102134117B1/en active IP Right Grant
- 2011-11-10 CN CN2011800647548A patent/CN103298467A/en active Pending
- 2011-11-10 KR KR1020207019691A patent/KR20200085936A/en active Application Filing
- 2011-11-10 ES ES16176846T patent/ES2865118T3/en active Active
- 2011-11-10 CA CA2818144A patent/CA2818144C/en active Active
- 2011-11-10 AU AU2011329209A patent/AU2011329209B8/en active Active
- 2011-11-10 KR KR1020137015295A patent/KR101891846B1/en active IP Right Grant
- 2011-11-10 KR KR1020217019125A patent/KR20210080591A/en not_active Application Discontinuation
- 2011-11-10 EP EP20200021.2A patent/EP3795154A1/en active Pending
- 2011-11-10 MX MX2013005439A patent/MX340859B/en active IP Right Grant
- 2011-11-10 RU RU2013124526/15A patent/RU2013124526A/en not_active Application Discontinuation
- 2011-11-10 KR KR1020247024450A patent/KR20240118184A/en active Search and Examination
- 2011-11-10 DK DK16176846.0T patent/DK3093017T3/en active
- 2011-11-10 CA CA3067290A patent/CA3067290A1/en active Pending
- 2011-11-10 SG SG10201509423XA patent/SG10201509423XA/en unknown
- 2011-11-10 BR BR112013012112A patent/BR112013012112A2/en not_active IP Right Cessation
- 2011-11-10 WO PCT/US2011/060236 patent/WO2012067941A1/en active Application Filing
- 2011-11-10 EP EP16176846.0A patent/EP3093017B1/en active Active
- 2011-11-10 SG SG2013038153A patent/SG190322A1/en unknown
- 2011-11-10 KR KR1020197034456A patent/KR102090441B1/en active IP Right Grant
- 2011-11-10 KR KR1020187023705A patent/KR102050187B1/en active IP Right Grant
- 2011-11-10 SG SG10201910521YA patent/SG10201910521YA/en unknown
- 2011-11-10 EP EP11785262.4A patent/EP2640382B1/en active Active
- 2011-11-10 KR KR1020227040513A patent/KR20220158876A/en not_active Application Discontinuation
- 2011-11-15 US US13/297,212 patent/US20120149747A1/en not_active Abandoned
- 2011-11-16 AR ARP110104278A patent/AR083893A1/en not_active Application Discontinuation
- 2011-11-16 TW TW100141941A patent/TW201304774A/en unknown
-
2013
- 2013-05-16 IL IL226384A patent/IL226384A/en active IP Right Grant
-
2015
- 2015-11-19 US US14/945,874 patent/US20160067222A1/en not_active Abandoned
-
2017
- 2017-01-05 US US15/399,460 patent/US20170172983A1/en not_active Abandoned
-
2019
- 2019-08-07 US US16/534,712 patent/US20200206193A1/en not_active Abandoned
-
2021
- 2021-02-18 US US17/179,271 patent/US20220008393A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1259250A1 (en) | Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienylmethylbenzene derivatives | |
| EP2416758B8 (en) | Antimycotic pharmaceutical composition | |
| HK1253355A1 (en) | Therapeutic compositions containing macitentan | |
| HK1246204B (en) | Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol | |
| EP2536697A4 (en) | Novel antifungal triazole derivatives | |
| SI3050564T1 (en) | Ester pro-drugs of (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl) methanol | |
| IL221212A0 (en) | Ethanol compositions | |
| HK1201759A1 (en) | 4-methylpyrazole formulations 4- | |
| EP2542082B8 (en) | PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-perillyl alcohol | |
| EP2394996B8 (en) | Phenylimidazole compounds | |
| HK1186177A1 (en) | Novel triazole compounds iii iii | |
| GB0806745D0 (en) | Novel imidazole derivatives | |
| IL226384A0 (en) | Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol | |
| HK1156250A1 (en) | Unit dosage of apadenoson | |
| EP2569320A4 (en) | (+)-3-hydroxymorphinan-based polycycle derivatives as neuroprotectants | |
| GB0904315D0 (en) | Novel imidazole derivatives | |
| AU2013257527A1 (en) | Unit dosage of apadenoson | |
| TWM388532U (en) | Wall sheet structure for architecture |